BIOTHERYX, INC.

San Diego, CA · Biotech · Private

Protein degrader therapeutics for cancer and inflammatory disease

Claim this profile

Follows are private to you and power your alerts

Updated · biotheryx.com

Sector
Biotech
Headquarters
San Diego, CA
Latest Form D
$92.1M, Jun 2021
Total capital
$93.8M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$93.8M
4 Form D · last Jun 2021
65 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
26
14 pending · first 2019
Rank in peer group#49 of 1449

Capital timeline

20142015201620172018201920202021FEDERAL ↑EQUITY ↓Cumulative $93.8M1st Form D$1M3rd Form D$500K4th Form D$92.1M
2014201620182020FEDERAL ↑EQUITY ↓Cumulative $93.8M3rd Form D$500K4th Form D$92.1M

Latest events

  • Private capital raisedForm D · SEC · 4th filing$92.1M
  • Private capital raisedForm D · SEC · 3rd filing$500K
  • Private capital raisedForm D · SEC · 2nd filing$150K
  • Private capital raisedForm D · SEC · 1st filing$1M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#49 · top 3%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Christopher A. DevineDirectorNamed in SEC Form D filings
  • David I. StirlingExecutive Officer, DirectorNamed in SEC Form D filings
  • David Stirling, PhDExecutive Officer, DirectorNamed in SEC Form D filings
  • Dung W.H. ThaiExecutive OfficerNamed in SEC Form D filings
  • Frank W.H. MercurioExecutive OfficerNamed in SEC Form D filings
  • Frank Mercurio, PhDExecutive OfficerNamed in SEC Form D filings
Show all 14 people
  • Jack A. NoelkeDirectorNamed in SEC Form D filings
  • Jaime A. DonadioExecutive OfficerNamed in SEC Form D filings
  • Kyle W.H. ChanExecutive OfficerNamed in SEC Form D filings
  • Kyle Chan, PhDExecutive OfficerNamed in SEC Form D filings
  • Lawrence ZaslowExecutive Officer, DirectorNamed in SEC Form D filings
  • Louis W.H. DeGennaroDirectorNamed in SEC Form D filings
  • Louis DeGennaro, PhDDirectorNamed in SEC Form D filings
  • Robert F. WilliamsonExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

USPTO · 26 granted of 40
Show all 40 patent records

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .